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2ABSTRACT
Antisense oligodeoxynucleotides (AS-ODNs) were used in combination with
transient functional expression of the cardiac Na+-Ca2+ exchanger (NCX1) to correlate
suppression of the Na+-Ca2+ exchange function with down-regulation of NCX1 protein
expression. In a de-novo expression system (Sf9 cells), a decrease in both, NCX1 mRNA and
protein after AS-ODN application was paralleled by diminished NCX1 activity, a typical
hallmark of an antisense effect. Although AS-ODN uptake was also efficient in rat neonatal
cardiac myocytes, in whole-cell extracts of these cells treated with AS-ODNs, the amount of
NCX1 protein determined in a quantitative binding assay remained almost unchanged,
despite a prompt loss of NCX1 function. Immunocytochemical staining of myocytes revealed
that most of the immunoreactivity was not localized in the plasma membrane, but in
intracellular compartments and was barely affected by AS-ODN treatment. However, the
small fraction of NCX1 located in the plasma membrane was significantly reduced. These
results indicate that the “functional half-life” of the NCX1 protein in the plasma membrane
of neonatal cardiac myocytes is surprisingly short, much shorter than reported half-lifes of
about 30 h for other membrane proteins.
31. INTRODUCTION
The Na+-Ca2+ exchanger (NCX) represents a transport protein that is expressed in the
cell membrane of almost any cell type. In cardiac muscle cells, the activity of the NCX is
particularly pronounced and the transporter is primarily responsible for the extrusion of Ca2+
from the cytosol during the relaxation of muscle force (for review see [1, 2]). The cardiac
subtype NCX1 mediates countertransport of Na+-and Ca2+ ions with a stoichiometry of 3:1,
thus generating a membrane current (INCX) [3-5] (but see [6]). To date there are still
considerable gaps in the understanding of the cellular and molecular function of the NCX1.
This is, at least in part, due to the lack of a specific pharmacological inhibitor. The emerging
knowledge about the cDNA encoding the cardiac NCX1 protein, which has been cloned and
sequenced in 1990, enabled several studies using molecular biology techniques in order to
overcome this limitation [7]. This includes site-directed mutagenesis [8-11], transgenic
animals overexpressing NCX1 [12, 13], the generation of knock-out mice [14, 15], and in
addition, antisense oligodeoxynucleotide (AS-ODN) strategies to block the de-novo synthesis
of NCX in cell cultures [16-19]. The AS-ODN approach led to an almost complete functional
suppression of NCX activity assessed by measuring INCX and by examining the Ca2+ transport
using laser-scanning confocal imaging [16]. However, some discrepancies with regard to the
protein stability and turnover of NCX1 in the cell membrane remain unsolved. The relatively
quick decrease in INCX, which was substantial at 24 h and almost complete at 48 h in AS-
ODN-treated neonatal cardiac cells indicated a comparably short half-life time (t1/2) of less
than 24 h [16]. In contrast, results from metabolic protein labeling studies suggested a t1/2 of
33 h for NCX1 [20]. In principle, the action mediated by the AS-ODNs could be due to
several mechanisms. The most obvious and expected one is the specific blocking and
degradation of newly synthesized NCX1 mRNA. In addition, the antisense oligonucleotides
4may have either a direct pharmacological effect on the NCX1 protein or unspecific toxic
effects as previously shown in other systems [21-23].
To address the question of specificity of the antisense approach, two models (neonatal
rat cardiac myocytes and insect Sf9 cells) and three methods (RT-PCR,
immunohistochemistry and a quantitative binding assay) were combined, all of which are
independent of the NCX1 function. The advantage of Sf9 cells is the lack of endogenous
NCX1 protein and the ease at which these cells can be infected with baculovirus containing
the cDNA for NCX1. In Sf9 cells expressing NCX1, the application of AS-ODNs resulted in
a significant reduction of NCX1 mRNA, of the de-novo synthesis of the exchanger as
evidenced by a quantitative binding assay and also by measuring the exchanger function. In
contrast, in neonatal cardiac myocytes, we observed that in whole-cell homogenates the total
amount of NCX1 epitopes recognized by the antibody was essentially unaltered after 48 h of
AS-ODNs treatment, while the functionally active fraction of NCX1 in the sarcolemma had
virtually disappeared. These observations provide a likely explanation for some of the
discrepancies in previous reports on the functional or biochemical half-life of NCX1.
52. METHODS
2.1. Oligodeoxynucleotide uptake by rat cardiac myocytes and SF9 cells
Antisense oligodeoxynucleotides (AS-ODNs), nonsense (NS) and mismatch (MM)
ODNs were identical to the ones described before [16]. The targeted sequence is part of the 3’
untranslated region of the cardiac Na+-Ca2+ exchanger (pos. 3065-3083, numbering according to
the rat sequence) [24]. Phosphorothioate AS-ODNs (HPSF: High Purity Salt Free) were
purchased from MWG Biotech (Ebersberg, Germany). In these ODNs, phosphorothioate groups
replace four of the internucleotide phosphate groups at each end (5’ and 3’), while all other
linkages are normal phosphoester bonds. The modified "backbone" of such a mixed
phosphorothioate oligo is resistant to the action of most exonucleases, but has a natural DNA
center. Stock solutions of purified ODNs (100-300 μM) were stored at 4°C or for longer periods
at -70°C. ODNs were added to the culture medium (3-5 μM final concentration for myocytes) for
24-48 h. Cultivated myocytes were then either fixed for immunohistochemistry or harvested for
the binding assay experiments. To check for ODNs uptake, we used either AS-ODNs against the
calcium-binding protein calretinin (CR) as described before or AS-ODNs against the NCX1,
additionally labeled with FITC at the 3' end [25]. The CR AS-ODNs have the same length and
approximately the same G/C content as the AS-ODNs directed against the NCX1 used for the
experiments. For SF9 cells higher concentrations of ODNs (20-30 μM) were used to obtain
comparable loading.
2.2. Neonatal rat cardiac myocytes
Primary cultures of neonatal rat cardiac myocytes from 2-3 day-old Wistar rats were
prepared using established methods [26]. The After enzymatic dissoziation, myocytes were
resuspened in medium M199 (Gibco) supplemented with 20 U/ml penicillin, 20 μg/ml
6streptomycin and 10% FCS, then ODNs were added after 2 h at an initial concentration of 1 or 3
μM. Cultures were maintained in an incubator (1.5% CO2) at 37°C for 24-48 h for experimental
purposes. For binding experiments, myocytes were seeded in 25 cm2 flasks at a density of 1-2 x
106 cells/ml and the AS-ODNs or NS-ODNs were added at an initial concentration of 1 or 3 μM
after 2 h. After 48 h, cells were washed with PBS, scraped off the flask, transferred into a 10 ml
tube and briefly centrifuged (3 min, 1000 rpm). The pelleted cells were resuspended in 5 ml of
Dulbecco’s Minimal Essential Medium (DMEM) supplemented with 5 % fetal calf serum (to
block unspecific binding sites) and 0.1 % saponin (to permeabilize spontaneously forming
membrane vesicles). This stock suspension was finally homogenized in a Potter-type glass-teflon
homogenizer and used for the binding assay.
2.3. Quantification of NCX mRNA by RT-PCR
To quantify NCX1 mRNA levels in ODNs-treated cells (Sf9 or cultured neonatal
myocytes), semi-quantitative RT-PCR with isolated total RNA was carried out. For first strand
synthesis, 5 μg of total RNA was reverse-transcribed using random primers and reagents
(RevertAid™ H- First Strand cDNA Synthesis Kit, MBI Fermentas, Lab Force, Nunningen,
Switzerland). Three different PCR reactions were carried out from the same batch (20 μl) of RT
product isolated from Sf9 cells (2 μl RT product per PCR). The first reaction was aimed at
amplifying part of the coding region (446–716) of the human NCX1 mRNA yielding a fragment
of 271 base pairs (bp). The second PCR reaction used primers that amplify a fragment of 232
base pair centered around the annealing site of the AS-ODN in the 3’UTR region of the NCX1
mRNA. Forward primer: ATCCTGCCTCTTTGTGCTCCTATGGCTC; reverse primer:
TACTTCGGCCCTAGTACAGAGTATGCTC. For the normalization of the RT-PCR reaction,
amplification of Sf9 60S acidic ribosomal protein P2 (60S RP) mRNA with primers 60SP2-5’
(AGACGTAGAGAAGATCCTCAGCTCTGTTGG)and60SP2-3’
7(TTGGTCTCCTTCTCTTCCTTCTTCTCCTCG) resulting in a band of 222 bp was carried out.
All PCR programs consisted of an initial denaturing step (2 min, 94°C) followed by cycles of
denaturing (20 s, 94°C), annealing at specific temperatures (40 s) and extension (40 s, 72°C).
The annealing temperatures were optimized for each primer set and were 63°C for NCX/C
(coding), NCX/3’UTR), rat NCX, 60S RP and 60°C for rat GAPDH. The optimal number of
PCR cycles (midpoint of logarithmic range) was found to be 25 cyles. Equal aliquots of either
NCX/C or NCX/3’UTR and 60S RP PCR product for Sf9 cell extracts and the previously
described reactions for rat NCX and GAPDH were separated on a 2% agarose gel [27]. Images
were acquired with a CCD camera and quantitatively analyzed using the BioRad software. For
Sf9 samples the ratio NCX/60S RP and for neonatal rat myocytes the ratio NCX/GAPDH was
calculated and the values for NS-ODNs treated samples were defined as 100%.
2.4. Protein binding assays
Binding experiments were carried out with the 3H-labeled high-affinity monoclonal
antibody R3F1 in order to quantify the expression of the NCX1 exchanger protein present in
whole cell lysates of neonate myocytes as described in detail previously or in NCX1 baculovirus-
infected Sf9 cells [28]. The results are expressed as the number of counts representing the
specifically-bound radiolabeled NCX1 antibody R3F1 per μg of protein of whole-cell
homogenate after subtraction of unspecific binding in the presence of a 50- to 100-fold excess of
non-labeled R3F1. The protein concentrations in the lysates were quantified using the Micro
BCA Protein Assay (Pierce, Rockford, IL) according to the protocol supplied by the
manufacturer.
82.5. Immunofluorescence studies
Neonatal rat cardiac myocytes were washed with CMF-PBS and fixed with methanol at -
20°C for 7 min. After washing with TBS (6 x 5 min, RT), the cells were incubated with the first
antibody against the rat cardiac NCX1 (mAb R3F1, mouse monoclonal antibody) [28]. The
monclonal antibody R3F1 was used at a dilution of 3.75 - 7.5 μg/ml in PBS + 10% bovine
serum. After incubation overnight at RT, cells were washed with PBS (6 x 5 min) and incubated
with the second antibody for 4 h in the dark. As second antibody, we used FITC-conjugated goat
anti-mouse IgG (Fc-specific, Jackson Immunoresearch, West Grove PA) at a dilution of 1:100.
Cells were washed once more as above and were visualized either on a Zeiss Axiovert (mag. 25
x) with the FITC-specific filters or on laser confocal microscopes (Zeiss, LSM 510).
2.6. Expression of the Na+/Ca2+ exchanger and AS-ODN uptake
The human NCX1 was cloned and expressed in HEK293 cells, the cDNA being then
subcloned into Baculovirus for expression in Sf9 cells [29]. Expression of NCX1 in Sf9 cells
from Spodoptera frugiperda was described in detail recently [30]. For expression of NCX1 and
AS-ODN uptake, Sf9 cells at a density of 1-2 x 106 cells/ml of serum free Grace’s medium were
transferred from the suspension culture to 25 cm2 culture flasks, wherein they were permitted to
attach for 40-60 min at 27°C. The supernatant was then replaced with fresh complete Grace’s
medium and ODNs were added after 24 h at an initial concentration of 20 μM (70% confluent
monolayer), in the absence or presence of 10 μg/ml DOTAP (Roche Diagnostics, Switzerland).
After incubation overnight, Sf9 cells were infected with MOI=5-10 from a recombinant
baculoviral stock (0.5-1 x 108 pfu/ml; viral titer determined by end-point dilution). The culture
flasks were maintained at 27°C in an incubator.
92.7. Functional tests of NCX1
The superfusion solution for functional tests of NCX1 contained (in mM): NaCl 140, KCl
5, CaCl2 1.8, MgCl2 1, HEPES 10, glucose 10. The pH was adjusted to 7.4 with NaOH.
Extracellular solutions were changed with a half-time (t1/2) of less than 0.5 s using a rapid
switching system. Li+ was used as a substitute for Na+ in [Na+]o-free solutions. The pipette filling
solution contained (in mM): Cs-aspartate 120, NaCl 10, K-ATP 5, Tetraethylammonium-Cl 20,
HEPES 10, K5-fluo-3 0.1 (Molecular Probes, Eugene, OR, USA), Na4-DM-nitrophen 2, reduced
glutathione (GSH) 2 and CaCl2 0.5 (pH 7.2, CsOH). Cells were loaded for at least 5 min by
dialysis. For the functional NCX1 tests, Sf9 cells were infected with MOI=1. All experiments
were carried out at ambient temperature (20°-22°C).
Flash-photolysis, INCX and Ca2+ measurements were described in detail elsewhere [31]. In
brief, the INCX was recorded in the whole-cell configuration of the patch-clamp technique and the
light from a xenon short-arc flash lamp (Strobex 238/278, Chadwick-Helmuth, El Monte, CA,
USA, 230 Ws, pulse duration 1 ms) was used to photolyze intracellular DM-nitrophen in an
epi-illumination arrangement on the confocal microscope (MRC1000; Biorad, Glattbrugg,
Switzerland). During loading with DM-nitrophen and between flashes, cells were held at a
membrane potential of -70 mV without correction for the junction potential. The membrane
potential was depolarized to –40 mV 3 s prior to the flash. Data were analyzed using Igor Pro
software (WaveMetrics, Lake Oswego, OR, USA). For Ca2+ time–course measurements, cells
cultures were loaded with fluo-3 AM (3-5 μM for 30-45 min at 30 oC). In addition, to obtain the
Ca2+ concentrations with a high temporal resolution rapid line-scans were performed (up to 500
Hz). [Ca2+]i was calculated according to the self-ratio method assuming a resting [Ca
2+]i of 100
nM and a Kd of fluo-3 for Ca
2+ of 400 nM. All values were expressed as means ± S.E.M.
Student’s paired t-tests were used to test for significance. Significance is given as P<0.05 or
<0.01, as indicated in the figure legends.
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3. RESULTS
3.1. AS-ODNs uptake, NCX1 immunofluorescence and NCX1 binding studies with myocytes
Uptake of the AS-ODN was tested with fluorescently labeled ODNs as shown before
[25]. Neonatal rat cardiac myocytes and SF9 cells were incubated with 3 μM or 30 μM FITC-
labeled ODNs, respectively, for 48 h, which resulted in a marked intracellular fluorescence that
was distributed throughout the cytoplasm, with a strong accumulation in perinuclear regions
(Fig. 1A a,b). For the detection of the cardiac NCX1 protein the monoclonal antibody mAb
R3F1, which recognizes epitopes present at the intracellular domain of the NCX1, was used (Fig.
1B) [28]. Cells were incubated with AS-ODNs (3 μM) for 48 h and compared to NS-ODNs (3
μM) treated myocytes. In control and AS-ODNs treated myocytes immunofluorescence was
detected in the perinuclear space. However, the two cell populations differed with respect to the
membrane-associated immunoreactivity. In about 60% of NS-ODNs-treated rat cardiac myocytes
maxima of fluorescence could be observed in the plasma membrane (Fig. 1Ba), whereas only
about 14% of NS-ODNs-treated myocytes showed membrane-associated immunoreactivity (Fig.
1Bb). Yet, no consistent differences in the overall intensities of the immunofluorescence between
AS-ODNs treated cells or NS-ODNs treated cells were found. This is in contrast to the
observation that under identical experimental conditions almost no NCX1 exchange function was
detectable in AS-ODN-treated cells. Since “quantitative” immunofluorescence is of limited value
for assessing protein expression levels, particularly in the case of membrane proteins, a protein-
binding assay was carried out using the radiolabeled antibody R3F1 to measure cellular NCX1
levels. Initially, complete binding curves for AS-ODNs-treated and NS-ODNs-treated control
cells were determined and were found to be almost identical (Fig. 1C). The plateau region of the
binding curve (maximal specific binding) was reached at mAb concentrations >1 μg/ml.
Therefore, a binding assay was carried out with a single free mAb concentration (1.5 μg/ml).
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Analysis of 20 samples from 8 independent experiments revealed no significant differences
between both groups (Fig. 1C, inset). From the immunocytochemistry results, it is evident that
the majority of NCX1 molecules are localized in organelles (ER, Golgi, lysosomes) and only a
small fraction of molecules is present in the plasma membrane. The lack of a difference in the
number of antibody binding sites between AS- and NS-ODNs-treated cells despite a significant
suppression of protein function is compatible with at least two possibilities: 1) A relatively small
fraction of active exchangers in NS-ODNs-treated cells with a short functional half-life in the
plasma membrane, that is absent or greatly diminished in AS-ODNs treated cells, might not be
detectable in the large background of inactive NCX1 molecules present in the plasma membrane
and other cellular locations; 2) AS-ODNs could promote a direct pharmacological inhibition of
NCX1 without affecting protein synthesis. But this is highly unlikely because AS-, NS- and
MM-ODNs all exhibited no toxic effects. To bypass the problems of high background levels of
endogenous NCX1 molecules, and to address the above question, we decided to use the Sf9 cell
system for the transient functional expression of NCX1. These cells have no endogenous NCX1,
can be infected with baculovirus encoding the human NCX1 as described before and are thus
ideally suited to investigate the effect of AS-ODNs on NCX1 biosynthesis directly [30].
3.2. Quantitative changes in Na+-Ca2+ exchanger mRNA after AS-ODNs treatment
To investigate the specificity of the antisense approach, i. e. whether AS-ODNs indeed
down-regulate NCX mRNA levels, semi-quantitative RT-PCR was carried out (Fig. 2A). For
normalization of RT-PCR reactions from different RNA samples, mRNA for 60S RP (Sf9 cells)
or GAPDH (myocytes) served as an internal standard. Each sample was analyzed twice
independently (RT and PCR reactions). For all PCR reactions 25 cycles proved to be the optimal
number (logarithmic phase). In non-infected Sf9 cells, no endogenous PCR product with the
NCX/C primers was amplified confirming that primers are specific for human NCX1 (Fig. 2A,
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CO 1–3). In infected and NS-ODN-treated Sf9 cells NCX1 signals were of variable intensities,
but all larger than the ones in AS-ODNs treated cells (Fig. 2A), which on average reached only
30.6 ± 2.1% (mean ± SEM, n=6; p <0.01) compared to NS-ODN-treated cells. A primer pair
embracing the AS-ODN annealing site (NCX/3’UTR) gave very consistent results (Fig. 2A),
28.7 ± 10.1% (p <0.001) compared to the NS-ODNs control. Thus, AS-ODNs treatment not only
degrades the 3’UTR region of the NCX1 mRNA, i.e. their target region, but affect the coding
region of NCX1 mRNA to a similar extent (approximately 70% reduction). AS-ODNs reduced
mRNA levels in rat neonate myocytes to a lesser degree. We measured approximately 25%
reduction in AS-ODNs-treated cells (p <0.05 vs. NS-ODN, not shown).
3.2. Binding assay for the monoclonal antibody mAb R3F1 to SF9 cells expressing NCX1
Sf9 cells infected with NCX1 baculovirus (MOI=1, 48 h) were immunostained with the
monoclonal antibody R3F1. Approximately 60% of Sf9 cells showed positive immunostaining.
Staining intensities reflecting expression levels between individual Sf9 cells varied considerably.
In all immunoreactive cells, the intracellular staining was present throughout the cytosolic space,
though not homogenously distributed and hence, probably associated with intracellular
compartments. Uninfected cells served as negative controls (Fig. 2B) and did not show specific
immunostaining. For antibody binding experiments, Sf9 cells were infected with the NCX1
cDNA-containing baculovirus at two dilutions (MOI=1 or 5). Sf9 cells were first preloaded with
ODNs (AS or NS) for 10–14 h. Then the cell cultures were infected with baculovirus and grown
for an additional 48 h (in the presence of ODNs) before they were harvested for the binding
assay. The specific R3F1 binding was assayed at 1.5-2 μg/ml radiolabeled mAb, i. e. in the
plateau range of the binding curves determined previously (see Fig. 1C). Initial experiments with
fluorescently labeled AS-ODNs (3 μM) revealed a significantly lower uptake of AS-ODNs in
Sf9 cells as compared to neonatal rat myocytes and thus, higher AS-ODNs concentrations were
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required (20-30 μM) to achieve comparable loading. Since AS-ODNs concentrations larger than
5 μM have been previously shown to induce nonspecific AS effects, functional assays in ODN-
treated Sf9 cells were carried out (see below) indicating that these concentrations do not affect
the viability of Sf9 cells. Under the condition of high multiplicity of infection with the
baculovirus (MOI=5) NCX1 expression was reduced by approximately 30% in AS-ODN- treated
(20 μM) cells as compared to NS-ODN (20 μM)-treated control cells (Fig. 2C). With the binding
in NS-ODN-treated cells set to 100%, mAb binding in native (uninfected) Sf9 cells was less than
3 %, while binding in AS-ODNs treated cells was reduced to 71.7 ± 9.4 %. It is important to note
that NS-ODN-treated cells rather than untreated NCX1-transfected Sf9 cells have to be taken as
the corresponding controls, since in initial experiments we observed that the presence of
polyanionic oligodeoxynucleotides had an effect on the rate of infection by the baculovirus (data
not shown). By lowering the MOI to 1, the reduction in NCX1 binding induced by AS-ODNs
was even more pronounced than at MOI of 5 (Fig. 2C). Under these conditions, an almost
complete down-regulation of NCX1 expression was observed, in line with the RT-PCR results as
expected for an AS-ODN effect. With the binding observed in NS-ODN-treated cells again set to
100%, the relative amount after AS-ODN treatment (18.1 ± 26.1 %, n=12) was almost identical
to the values in uninfected control Sf9 cells (13.4 ± 13.3 %, n=3), both values being not
significantly different from zero.
3.3. Blocking effects of AS-ODNs on NCX1 function
For functional studies, cultures of control Sf9 cells exposed to NS-ODNs (20 μM) and of
those exposed to AS-ODNs (20 μM) were set up in parallel. For an initial examination of the
NCX1 activity, the Na+ concentration gradient across the sarcolemma of fluo-3 AM loaded cells
was reversed by replacing extracellular Na+ with Li+. In the presence of extracellular Ca2+, this
maneuver induced Ca2+ entry into cells via NCX1 operating in the “reverse mode”. Because of
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the exchange stoichiometry of 3 Na+: 1 Ca2+, an outward membrane current is generated in the
Ca2+ influx mode, and an inward current is produced when Ca2+ moves in the outward direction.
The activity of the exchanger in the reverse mode was estimated by determining the initial rate of
rise in [Ca2+]i (d[Ca
2+]i/dt), measured as changes of fluo-3 fluorescence with confocal microscopy
(Fig. 3). The Ca2+ entry and removal from the cytosol were almost exclusively due to the NCX1
activity as indicated by the almost complete absence of a detectable [Ca2+]i decay when NCX1
was suppressed (see below) or in native Sf9 cells that show no basal NCX1 activity (data not
shown). Figure 3A and B depict cell images and representative Ca2+ signals recorded from NCX1
expressing Sf9 cells after a 48h treatment with NS-ODNs (control) or from cells that had been
exposed for the same time period to AS-ODNs. During the [Na+]o-free period, [Ca
2+]i rose by
about 1.4 μM in control cells. Superfusion with [Na+]o containing solution led to a monotonic
decay of [Ca2+]i to resting levels. In cells exposed to AS-ODNs (20 μM for 36 h), [Ca2+]i rose to a
significantly lower final level (190 nM). This was quantified by analyzing the Ca2+ transport
(d[Ca2+]i/dt, Ca
2+ influx, Fig. 3C). After 24 h of NCX1 expression, the NCX1-mediated Ca2+
influx in AS-ODN-treated Sf9 cells was reduced to about 34% of that in NS-ODN-treated cells.
After 48 h of NCX1 expression d[Ca2+]i/dt obtained in NS-ODNs was about 5-times larger than
after 24 h, indicative of robust expression of the exchanger and incorporation of functional NCX
molecules into the plasma membrane. On the other hand, the rate in AS-ODN-treated cells was
only about 9% of that in NS-ODNs treated ones (Fig. 3C). In NS-ODNs treated cells, repeated
application of [Na+]o containing solution demonstrates that NCX1-mediated Ca
2+ transport can be
evoked several times (Fig. 3D). Interestingly, the second Ca2+ transient was reduced in
amplitude, probably due to the reduced transmembrane concentration gradient for Na+.
A specific test for the NCX function is the UV-flash photolysis approach to elevate
[Ca2+]i and then to follow the time-course of the [Ca
2+]i decay mediated by exchanger [27]. For
these experiments, Sf9 cells were used and the data were obtained after 48 h of NCX1
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expression. Intracellular Ca2+ concentration jumps were generated with UV-flash photolysis of
caged Ca2+. For this purpose, single cells were dialyzed with a pipette-filling solution containing
2 mM DM-nitrophen and 0.5 mM Ca2+ (in addition to the Ca2+ indicator fluo-3). Upon applying a
flash of UV-light, [Ca2+]i jumps of about 180 nM were induced (Fig. 4A and B). In NS-ODNs
treated cells, [Ca2+]i decayed to basal levels within 3 seconds (=470 ± 28.8 ms, Fig. 4A). This
[Ca2+]i step resulted in an INCX of 14.95±2.9pA (n=5). The control NS-ODNs did not
significantly affect NCX1 function when compared to previous results obtained in the absence of
ODNs. In cells exposed to AS-ODNs (Fig. 4B), a similar flash resulted in a comparable jump in
[Ca2+]i, but the decay was significantly slower and, during the time of monitoring (approximately
1 min), did not reach basal [Ca2+]i. The initial Ca
2+ transport rate (d[Ca2+]/dt, Ca2+ efflux) in AS-
ODN-treated cells was only 11% of that in NS-ODN-treated ones. The corresponding INCX was
reduced to about 26% (Fig. 4C and D). The INCX was normalized to the cell membrane
capacitance (7.35±0.28 pF, n=20) using cell geometry parameters (diameter: 15.38±3.1 μm,
n=20) obtained from the confocal images. Although, probably additional Ca2+ transport systems
working on slow time scale and contributing to the removal of Ca2+, these findings suggest that
the expression of NCX1 after AS-ODNs treatment was significantly diminished as evidenced by
the reduced Ca2+ decay rate and the much smaller INCX.
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4. DISCUSSION
In whole-cell extracts of neonatal rat cardiac myocytes treated with NCX1-specific
AS-ODNs, the amount of immunoreactive exchanger protein remained almost unchanged
despite efficient AS-ODN uptake and despite a prompt loss of NCX function. To explain this
discrepancy, we combined 3 independent quantitative methods (RT-PCR, immunohisto-
chemistry and a radioligand binding assay) for measuring NCX1 expression with functional
tests based on flash-photolysis of caged Ca2+ and confocal imaging [28]. Our strategy also
included AS-ODN suppression of de-novo protein expression in a background-free
heterologous expression system. This approach involving several biophysical and an array of
complementary molecular biology techniques has allowed us to derive novel conclusions
regarding the NCX1 protein turnover in cardiac muscle cells.
4.1. “Mechanism” of antisense inhibition in neonatal myocytes and in Sf9 cells expressing NCX1
Interestingly, confocal images of R3F1 mAb-immunostained neonatal rat myocytes
revealed that a large fraction of NCX1 immunoreactivity was localized to the plasma membrane
and in cytoplasmic regions, with a high density in the perinuclear region, previously reported as
“organized in reticular patterns” [32]. However, no striking differences in the intensity of overall
staining were detected between AS- and NS-ODN-treated cultured myocytes. Since the NCX1
activity is mediated only by the subpopulation of exchanger molecules, which are both I)
localized in the sarcolemma and II) functional, our results suggested that this fraction of NCX1
population is small compared to the amount of immunoreactive protein detected by the R3F1
antibody.
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A way out of the dilemma was to investigate the effect of NCX1 AS-ODNs in Sf9 insect
cells i.e. in a cellular system without native NCX1 activity, which would allow us to verify that
the AS-ODN effect was caused by the degradation of NCX1 mRNA leading to decreased
expression levels and subsequently reduced activity of NCX1 protein.
In order to effectively apply the antisense approach on NCX1-infected Sf9 cells, several
points have to be considered. The first is the kinetics of infection, which depend on the
multiplicity of infection (MOI) of the inoculum and, related to that, the delay until functionally
active NCX1 molecules are expressed in the plasma membrane. Secondly, the kinetics of uptake
of the ODNs have to be monitored, which depend on the extracellular ODN concentration and
the type of reagents used to facilitate ODN uptake (e. g. lipofection reagents). We found that the
uptake of fluorescently labeled ODNs in Sf9 cells was considerably less efficient than in
neonatal cardiac myocytes, necessitating extracellular ODN concentrations of 30 μM (instead of
3 μM) for comparable intracellular fluorescence intensities. Using this AS-ODN loading
protocol, RT-PCR amplification of either the region containing the AS-ODNs binding site or a
region within the coding part of the NCX1 mRNA resulted consistently in a signal approximately
70% weaker in Sf9 cells treated with AS-ODNs than in NS-ODNs-treated cells. In the protein
binding assay, the efficiency of the AS-ODNs to block the de-novo synthesis of NCX1 protein
was clearly dependent on the MOI. At a MOI of five, NCX1 protein levels in AS-ONDs treated
cells were  30 % lower than in NS-ODN-treated cells and at MOI of one, NCX1 protein levels
determined after 48 h of AS-ODN-treatment ranged barely above the nonspecific background
value obtained for uninfected Sf9 cells. Hence, at a low to moderate MOI the NCX1 synthesis
can be almost completely blocked by AS-ODNs. Thus, RT-PCR and protein binding results fully
support the notion that AS-ODNs efficiently suppress NCX1 expression. Effective suppression
of NCX1 expression was also confirmed by two functional assays (1) testing the reverse mode of
the NCX1 protein in the absence of external sodium and (2) measuring the forward mode by
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rapidly increasing [Ca2+]i by flash photolysis of caged Ca
2+. Both, Ca2+ efflux as well as Ca2+
influx were similarly reduced in AS-ODN-treated Sf9 cells. The almost complete blocking of
NCX1 synthesis observed at both, mRNA and protein levels in AS-ODNs treated cells clearly
parallels the reduced NCX1 function.
4.2. Rapid turnover of the “functional” NCX1
If we assume the same antisense mechanism, a reduction of the protein expression, also
to be present in neonatal cardiac myocytes (as also evidenced by decreased mRNA levels), how
can we reconcile the apparent paradox that NCX function is dramatically reduced after 48 h of
AS-ODNs treatment, while the total amount of NCX1 measured in the binding assay is not
significantly affected?
In neonatal cardiac myocytes NCX1 immunoreactivity (Fig. 1) resides in various
organellar compartments most likely including SR, Golgi, vesicular compartments transporting
the NCX1 protein to or from the plasma membrane and finally in the plasma membrane. Yet the
only functionally relevant species is the small fraction of NCX1 protein located in the plasma
membrane. This distribution of NCX1 is not surprising, since the endoplasmic reticulum has
important functions as a quality-control system for newly synthesized proteins, so that only
native conformers reach their final destinations such as the plasma membrane. Non-native
conformers or misfolded proteins are either retained or degraded, respectively and apparently, a
large fraction of ER-synthesized proteins fail to fold and mature properly (reviewed in [33]).
Since NCX1 protein turnover has been determined in whole-cell lysates, the relatively long t1/2
(33 h) is fully compatible with a model consisting of a rather short protein synthesis time and a
rapid insertion into the plasma membrane, while a relative slow process accounts for membrane
protein retrieval leading to either recycling or degradation of the NCX1 molecules. Such a model
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is further supported by our observation of a distinct loss of membrane-associated
immunoreactivity in AS-ODN-treated cardiac cells. Even among the population of NCX
molecules present in the plasma membrane, only a fraction might be functionally active. This is
in line with previous findings, where the effect of AS-ODNs on target protein levels was found
to be smaller than the one calculated from the loss of functional activity [34]. Hence, the
“functional” half-life of the NCX1 protein measured as exchange activity and the half-life
determined by [35S]methionine labeling may well have significantly different time scales.
Additionally, a relative resistance of the antibody epitope against proteolytic cleavage during
degradation might help to explain the discrepancy between the levels of NCX1 immunoreactivity
and NCX1 function after AS-ODN treatment.
4.3. Comparison with previous studies
The half-life (t1/2) of the NCX1 protein in neonatal cardiac cells was previously reported
by different laboratories to range between 10-33 h, possibly depending on the methodology
applied [16, 20]. Although the t1/2 value found in our study is in line with previous reports on t1/2
values of other membrane proteins, conclusions need to be drawn with some caution [35]. In
most reports, cells are metabolically labeled with a pulse of 35S[methionine] and then the time
course of the disappearance of incorporated radioactivity in the molecules of interest is
monitored by immunoprecipitation. Earlier studies have shown that several proteolytic fragments
of the exchanger observed in Western blots of NCX1 protein preparations retained
immunoreactivity towards antibodies, such as R3F1, with epitopes within the intracellular
hydrophilic loop [36, 37]. All evidence obtained previously suggests that the de-novo synthesis
in neonate cardiac myocytes is fast and the functional half-life of NCX1 in the plasma membrane
in these cells is short, which is compatible with an almost complete loss of activity 48 h after
AS-ODNs treatment. Besides the putative mechanisms discussed above, the rather slow time
20
course of NCX1 protein rundown in the study of Slodzinski et al. 1998, may well be explained
by the lower concentration of AS-ODNs used (0.5 μM versus 3 μM in the present study) [20].
On the other hand, Takahashi et al. 1999, using a concentration of 10 μM reported a decrease in
the level of NCX1 expression in the order of 20% within 24h [38].
Our results indicate that by far the largest fraction of NCX1 immunoreactivity is not
residing in the plasma membrane and that the functional NCX1 proteins have a very high
turnover rate such that a blockage of protein synthesis is quickly translated to impaired
NCX1 function. Whether this high turnover rate is specific for neonate cardiac myocytes and
why this energetically unfavorable mechanism is maintained needs to be addressed in further
experiments.
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7. FIGURES
Figure 1: A: Intracellular localization of a FITC-labeled AS-ODNs (identical sequence
as the AS-ODNs used in the functional assays). Sf9 cells (a) and neonatal myocytes (b) were
incubated with the FITC-labelled AS-ODNs (3 μM, 30 μM respectively) for 48 h in the
culture medium and analyzed by confocal microscopy. B: Immunostaining of rat neonatal
cardiac myocytes and binding assay with the monoclonal antibody R3F1 (3 μM) directed
against the NCX: Ba) NS-ODNs and Bb) AS-ODNs. Insets: Profile of fluorescence intensity
distribution. In NS-ODNs-treated rat cardiac myocytes maxima of fluorescence can be
observed in the plasma membrane and in cytoplasmic regions. However, the
immunofluorescence approach failed to discriminate between the overall expression of the
NCX1 in AS-ODNs-treated and NS-ODNs-treated rat cardiac myocytes. Bc: Membrane-
associated immunoreactivity in NS-and AS-ODN-treated rat cardiac myocytes (n=60); C:
mAb R3F1 binding curves. Control NS-ODNs and AS-ODNs-treated rat cardiac cell
homogenates were equilibrated at 35°C with 3H-labelled mAb R3F1 in the presence and
absence of 100 μg/ml unlabeled mAb. Unspecific binding is subtracted throughout. The
curves give nonlinear least-square fits to the data points. Inset: Maximal binding was
determined in 8 experiments at 1.5-2 μg/ml mAb in the plateau range of the binding curves.
After treatment with an AS-ODN directed against the NCX1 mRNA the binding affinity of
the specific antibody remained unchanged.
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Figure 2: A : Semi-quantitative RT-PCR to quantify NCX1 mRNA levels; B:
Immunodetection of the NCX1 protein expression in Sf9 cells (MOI=1, 48 h) with the
monoclonal antibody R3F1. Sf9 cells with strong NCX1 immunoreactivity (right) as well as
cells with no or very low NCX1 expression were observed in the same preparation.
Approximately 60% of Sf9 cells showed positive immunostaining against the NCX1; C:
Maximal R3F1 binding was determined at 1.5-2 μg/ml mAb in the plateau range of the
binding curves (see Fig. 1C). Experiments with Sf9 cells (native Sf9 cells, NS-ODNs and AS-
ODNs treated cells) with no endogenous NCX1 under 2 conditions: high and low MOI: A
more pronounced AS-ODNs effect was found under low MOI conditions (NS: n=6, AS: n=12,
*P<0.05).
Figure 3: Reduced Ca2+ transport (influx) via NCX1 in AS-ODNs treated Sf9 cells
expressing NCX1. A, B from left to the right: Overview confocal images of NS-ODNs
(control cells, treated for 50 h, 30 μM) and AS-ODNs treated Sf9 cells (48 h, 30 μM) and the
time course of [Ca2+]i changes after superfusion with [Na
+]o free solution (activation of the
NCX Ca2+ influx mode). The black bar denotes the time period of superfusion with [Na+]o
free solution; C: Ca2+ transport (Ca2+ influx) mediated by the NCX1 after 24 h (NS-ODNs:
10.31±7.14 nM/s, n=25; AS-ODNs: 3.47±2.4, n=8) and 48 h (NS-ODNs: 110.63±7.14
nM/s, n=16; AS-ODNs: 9.9±6.7, n=16; **P<0.01) under control conditions (30 μM NS-
ODNs) and after 30 μM AS-ODNs treatment, respectively. D: Time course of repetitively
activated NCX1 function (Ca2+ influx) by superfusion with [Na+]o free solution in NS-ODNs
pre-treated (30 μM) Sf9 cells expressing NCX1 for 24 h. The reduced second [Ca2+]i peak can
be explained by reduced driving force due to the loss of intracellular Na+. MOI=1.
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Figure 4: AS-ODNs significantly suppress the NCX1 function induced by flash-
photolysis of caged Ca2+. A and B show from top to bottom: [Ca2+]i jumps induced by
photorelease from 2.0 mM DM-nitrophen, the corresponding line-scan image of the fluo-3
fluorescence change and the corresponding NCX current elicited at –40 mV in 30 μM NS-
ODNs (control) and 30 μM AS-ODNs treated Sf9 cells expressing NCX1; C: comparison of
the Ca2+ transport (Ca2+ efflux, dCa2+/dt) in control and AS-ODNs treated Sf9 cells expressing
NCX1; and D: NCX1 current density. The Ca2+ transport as well as the exchanger current can
be effectively blocked by AS-ODNs treatment of about 48 h (**P<0.05 vs NS-ODN treated
cells, n=5).
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